ADC Manufacturing CDMOs

AbbVie Contract Manufacturing (AbbVie CMO)

Italy

AbbVie Contract Manufacturing is an embedded CMO within AbbVie, providing third-party contract manufacturing services for over 40 years across 12 locations in the US and Europe. They offer services spanning antibody drug conjugates, aseptic fill/finish, biologics (mAbs and derivatives), custom API, eye care, hot melt extrusion, HPAPI, and oral solid dose manufacturing.

Abzena

United States

Abzena is a leading complex biologics and bioconjugates CDMO+CRO headquartered in the UK with 20+ years of experience. They provide fully integrated services from antibody discovery through commercial GMP manufacturing, specializing in ADCs, AOCs, RDCs, mAbs, fusion proteins, and bispecifics. With over 1,400 lead candidates discovered, 100+ production cell lines developed, and 2,000+ bioconjugates produced, they operate state-of-the-art facilities in San Diego, Bristol (PA), and Cambridge (UK).

AGC (AGC Biologics & AGC Pharma Chemicals)

United States

AGC Biologics is a leading global CDMO providing contract development and manufacturing services for biologics, cell and gene therapies, and advanced modalities. With facilities in Seattle, Copenhagen, Heidelberg, Milan, Chiba, and Yokohama, AGC operates mammalian and microbial expression systems and offers end-to-end services from process development through commercial-scale manufacturing.

Ajinomoto Bio-Pharma Services

Belgium

Ajinomoto Bio-Pharma Services (Aji Bio-Pharma) is a fully integrated global CDMO providing comprehensive development and cGMP manufacturing services for both small and large molecule pharmaceuticals. With facilities in Belgium, the United States, Japan, and India, the company offers platform technologies including oligonucleotide manufacturing, ADC conjugation, small molecule API synthesis, and aseptic fill-finish services. The Althea fill-finish site was acquired by PCI Pharma Services.

Altruist Biologics

China

Altruist Biologics is a China-based biologics CDMO backed by Innovent Biologics, offering end-to-end development and GMP manufacturing for monoclonal antibodies, bispecific/multispecific antibodies, fusion proteins, recombinant proteins, and antibody-drug conjugates (ADCs). The company operates large-scale facilities in Suzhou (60,000L) and Hangzhou (172,000L) with bioreactors from 1,000L to 20,000L, achieving a 99.8% batch success rate and 180+ global regulatory approvals.

Aragen Life Sciences Ltd.

India

Aragen Life Sciences Ltd. (formerly GVK Biosciences) is a CRDMO (Contract Research, Development, and Manufacturing Organization) headquartered in Hyderabad, India, with over 4,000 scientists. They provide integrated services spanning small molecules and large molecules (biologics) from discovery through commercialization. Their capabilities include HPAPI handling (cytotoxics, immunosuppressants, ADC toxins), particle science, process validation, and IND enabling services across multiple FDA-registered facilities.

Ardena

Belgium

Ardena is a Belgian-headquartered global specialist CDMO and CRO focused on precision medicine development of complex and innovative molecules, with a leading position in nanomedicine development. They offer integrated services spanning drug substance manufacturing, drug product manufacturing (oral solids, injectables, nanomedicines), bioanalytical testing, and CMC regulatory support. Their multi-site network includes capabilities for HPAPI manufacturing, spray drying, hot melt extrusion, and aseptic sterile manufacturing.

AsymBio (Asymchem Group)

China

AsymBio, a strategic business unit of Asymchem Group (stock code: 002821.SZ / 6821.HK), is a biologics CDMO focused on antibodies, recombinant proteins, bioconjugates (including ADCs), and mRNA. They provide end-to-end services from cell line construction through commercial manufacturing, with a 130,000+ sq meter Shanghai Fengxian facility featuring 200L/500L/2000L single-use bioreactors. They have supported FDA IND approvals for partners including Radiopharm Theranostics.

Aton Biotech

China

Aton Biotech is a China-based biologics CDMO backed by Henlius Biotech, offering one-stop solutions from early development to commercial production. They provide services in process development, GMP manufacturing, analytical testing, and ADC development. With access to up to 144,000L bioreactor capacity from parent company Henlius, they focus on monoclonal antibodies, recombinant proteins, and antibody-drug conjugates.

BioDuro (BioDuro-Sundia)

China

BioDuro-Sundia is a global CRDMO (Contract Research, Development and Manufacturing Organization) offering end-to-end integrated drug discovery and development services. The company provides comprehensive chemistry services (medicinal, peptide, synthetic, analytical, scale-up), biology/DMPK, drug substance process R&D and manufacturing, drug product formulation and manufacturing, and biologics services. Has acquired a US-based Phase III/commercial drug product manufacturing facility.

BioTechnique LLC

United States

BioTechnique LLC is a full-service CRDMO based in York County, Pennsylvania, specializing in cytotoxic and therapeutic sterile injectable fill-finish services. The company provides services from investigational/clinical through to final marketed products, handling both small and large batch sizes. BioTechnique operates an FDA-registered facility with capabilities spanning sterile manufacturing, lyophilization, and high-potency compound handling.

Bryllan

United States

Bryllan is a US-based CDMO specializing in the production and filling of potent and cytotoxic compounds, with a focus on aseptic powder and liquid filling for complex drug and device combination products. The company operates a high-containment, state-of-the-art facility in Brighton, Michigan, supporting both clinical and commercial supply of ADCs and other cytotoxic products.

BSP Pharmaceuticals

Italy

BSP Pharmaceuticals is an Italian CDMO specializing in cytotoxic, ADC (antibody-drug conjugate), and non-cytotoxic sterile injectable manufacturing. The company provides development, clinical, and commercial supply services including API synthesis, ADC conjugation and fill/finish, and oral solid dose manufacturing, with FDA and EMA approved facilities near Rome.

CARBOGEN AMCIS

CHina

CARBOGEN AMCIS is a leading CDMO offering drug substance and drug product development and manufacturing services from early development through commercialization. Part of the Indian Dishman Carbogen Amcis group, the company has facilities in Switzerland, France, UK, Netherlands, and China, specializing in complex small molecule APIs, ADC payloads, and sterile drug products.

Catalent Pharma Solution

Argentina

Catalent is a leading global CDMO trusted by pharma, biotech, and self-care companies to accelerate the development, manufacturing, and delivery of products that improve lives. With a worldwide network of facilities, advanced technologies, and deep expertise, Catalent provides integrated end-to-end solutions spanning oral dose, biologics, specialty therapies, cell and gene therapy, and clinical supply. The company partners with innovators from early-stage design through commercial manufacturing.

Celltrion

South Korea

Celltrion is a major South Korean biopharmaceutical company offering CDMO services for biologics, biosimilars, and small molecules. The company operates production capacities from 1,000L to 15,000L with a 98.5% batch success rate across 2,100+ cGMP drug substance batches, holding 400+ regulatory approvals in 90+ countries. Celltrion recently acquired Eli Lilly's Branchburg, New Jersey facility and launched Celltrion BioSolutions as a dedicated CDMO subsidiary, with plans to expand DS capacity to 132,000L by 2030.

Cohance Lifesciences

India

Cohance Lifesciences is a global CDMO platform specializing in small molecule APIs, antibody-drug conjugates (ADCs), and nucleic acid chemistry, serving customers in nearly 60 countries with 80+ molecules in their portfolio. The company operates 20+ manufacturing and R&D facilities across India and the US, with multiple USFDA and EDQM-accredited sites, offering end-to-end solutions from drug discovery through commercialization including high-potent APIs (OEB 4 & 5), oligonucleotides, and finished dosage forms.

Lonza

Switzerland

Lonza is a pioneer and world leader in the CDMO industry, founded in Switzerland in 1897. The company provides integrated development and manufacturing services across biologics, small molecules, cell and gene therapy, mRNA, and bioconjugates (ADCs/HPAPIs). With over 20,000 employees across five continents, Lonza serves the global pharmaceutical, biotech, and nutrition industries with end-to-end capabilities from early development to commercial-scale manufacturing.

Pfizer CentreOne

Belgium

Pfizer CentreOne is a global CDMO embedded within Pfizer, specializing in commercial manufacturing of oral solid doses, sterile injectables, biologics including monoclonal antibodies, and antibody-drug conjugates. It leverages Pfizer's global manufacturing network across six continents with cGMP-compliant sites and over 170 years of pharmaceutical manufacturing expertise, backed by $1B+ annual manufacturing investments.

Pharmaron

China

Pharmaron is a premier life science CRO/CDMO providing comprehensive R&D and manufacturing services across the entire drug discovery to commercialization process. The company serves small molecules, biologics, ADCs, cell & gene therapies, and protein degraders. It offers laboratory services, chemistry/manufacturing/controls (CMC), clinical development, and biologics/CGT manufacturing. Pharmaron acquired a commercial API manufacturing facility in the UK and operates a gene therapy CDMO in Liverpool with a 20-year track record. The company has over 20 years of experience across 7+ facilities in the UK, US, and China.

Pierre Fabre (CDMO)

France

Pierre Fabre CDMO is the contract development and manufacturing arm of the Pierre Fabre Group, a French pharmaceutical and dermo-cosmetics company. Offers over 20 years of CDMO services across pharma and non-pharma active ingredients, dry forms, non-sterile liquids, and biologics including monoclonal antibodies and ADCs. Operates R&D site in Toulouse and 3+ industrial sites in France. Expertise spans extraction, chromatographic purification, chemical synthesis, cytotoxic compound production, plant cell culture, and supercritical CO2 technology. Manufactures 2,100 metric tons of plant extracts and 100+ active ingredients annually.

Porton Pharma Solutions

China

Porton Pharma Solutions is a global CDMO headquartered in China with over 4,300 employees and operations in the US, Europe (Slovenia), and China. They offer end-to-end services across small molecules, tides (peptides/oligonucleotides), biologics and conjugates (ADCs), and advanced therapy medicinal products. Technical solutions include crystallization, bio catalysis, metal catalysis, flow chemistry, preparative chromatography, milling, and chemical engineering. FDA-registered with 4 FEI numbers for API manufacture, they have 3 FDA inspections with clean outcomes (1 NAI, 2 VAI).

Simtra BioPharma Solutions

Germany

Simtra BioPharma Solutions is a global CDMO focused exclusively on sterile injectable drug products. With over 65 years of expertise, Simtra offers formulation development, lyophilization cycle optimization, technology transfer, analytical services, fill/finish operations, specialized containment, and global regulatory support. They handle cytotoxics, highly potent compounds, biologics, vaccines, small molecules, ADCs, and diluents. They have a strategic alliance with MilliporeSigma for ADC manufacturing. The company has transferred 60+ ADC candidates including six commercial products to their German site.

Symbiosis Pharmaceutical Services

United Kingdom

Symbiosis Pharmaceutical Services is a world-class sterile fill-finish CDMO based in Stirling, UK, specializing in the GMP manufacture of liquid and lyophilized biological and small molecule drug products. The company serves clinical trial and commercial scale with FDA-inspected and MHRA-licensed facilities. Symbiosis has manufactured its first 10,000-vial commercial batch for a cancer immunotherapy currently in Phase III trials. The company handles a full range of biologics including ATMPs, viral vectors, mAbs, ADCs, RNA/peptide therapies, and vaccines.

Syngene International

India

Syngene International is a leading Indian Contract Research, Development and Manufacturing Organization (CRDMO) that provides integrated services spanning drug discovery through commercial manufacturing for both small and large molecules. The company has long-term research collaborations with Bristol Myers Squibb (extended until 2035) and Amgen. Syngene recently opened its first US manufacturing facility in Rockville, Maryland, and added a bioconjugation suite in Bengaluru for end-to-end ADC development. The company has 20 kL single-use drug substance capacity for biologics.

WuXi Biologics

China

WuXi Biologics is a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) for biologics, with over 12,000 employees across the US, Ireland, Germany, China, and Singapore. The company provides end-to-end solutions from discovery through commercial manufacturing for biologics including monoclonal antibodies, bispecifics, ADCs, vaccines, and mRNA products using both mammalian and microbial expression systems.

Axplora

Germany

Axplora is a global CDMO specializing in API manufacturing, headquartered in Raubling near Munich, Germany. The group comprises Axplora, Novasep CDMO, and Farmabios, with over 2,000 employees across 10 manufacturing sites on three continents serving 900+ customers. Axplora has particular expertise in chromatography-based separations and small molecule manufacturing, with strong positions in oncology (ADC payloads via Novasep's Le Mans site) and GLP-1 receptor agonist manufacturing (EUR 50M investment at Mourenx, France). The company manufactures both specialty API products and provides contract manufacturing services, with capabilities ranging from lab-scale development through large-scale commercial production including anticancer drugs and complex APIs.

Celonic

Germany

Celonic is a Swiss-based 'Pure Play' biologics CDMO offering end-to-end drug substance development and manufacturing solutions for monoclonal antibodies, bispecifics, and other complex molecules. The company is a pioneer in next-generation bioprocessing technologies including process intensification and full perfusion. Celonic operates facilities in Basel, Switzerland and Heidelberg, Germany, and has a strategic alliance with CARBOGEN AMCIS for integrated ADC development and manufacturing.

Cerbios‑Pharma SA

Switzerland

Cerbios-Pharma SA is a privately held Swiss CDMO based in Barbengo-Lugano with over 40 years in the pharmaceutical industry, now part of the HAS Group. The company specializes in the development and manufacture of chemical and biotechnological APIs, with particular expertise in HPAPIs (high-potency APIs), ADC payloads and conjugation, and recombinant proteins and antibodies. Cerbios offers both chemical synthesis and biological manufacturing capabilities, including living microorganism-based products.

ChemPartner

China

ChemPartner is a science-based, technology-driven global CRO and CDMO with over 20 years of experience and 2,000+ scientists. The company provides end-to-end drug discovery through IND services for small molecules and biologics, including antibody discovery, ADC development, and cGMP biologics manufacturing. ChemPartner has expanded its biologics CDMO capabilities with a 67,000 sqm facility in Qidong, China and a new R&D center in Boston.

Creative Biolabs

United States

Creative Biolabs is a US-based ISO 9001:2015 certified CDMO providing comprehensive biotechnology and pharmaceutical services including antibody discovery, viral vector CDMO solutions, CAR-T cell therapy manufacturing, and custom bio-manufacturing. The company offers end-to-end services from discovery through cGMP production for biologics including AAV, lentivirus, adenovirus, and HSV vectors.

Dragon Sail Pharmaceutical

China

Dragon Sail Pharmaceutical Co., Ltd. is a Chinese CDMO founded in 2016, focusing on antibody drug CDMO/CMO services from sequence to IND through commercial production. The company built China's first cross-free antibody plant in the Shanghai Lin-gang Special Area with a total investment of nearly RMB 700 million and a maximum production scale of 12,000L.

Gannet BioChem

United States

Gannet BioChem is a specialty CDMO based in Huntsville, Alabama, focused on polymer science, PEG chemistry, and bioconjugation. Built on the legacy of Shearwater Polymers and Nektar Therapeutics, the company provides end-to-end capabilities from early discovery through cGMP and commercial manufacturing of activated polymers, PEG reagents, and bioconjugates. The FDA-inspected facility spans over 124,000 square feet across four buildings and has supported 50+ global partners.

Icosagen

Estonia

Icosagen is a private, science-driven biologics CRDMO headquartered in Estonia, combining CRO and CDMO capabilities under one roof. With 25 years of expertise, the company provides integrated services spanning antibody discovery, protein production, cell line development, ADC conjugation, process development, and GMP manufacturing for mammalian protein drug candidates.

medac GmbH (medac CDMO)

Germany

medac GmbH operates a dedicated CDMO division (medac CDMO) offering end-to-end sterile injectable manufacturing services from clinical supply through large-scale commercial production. Based in Germany with facilities in Wedel and Dessau (Germany) and Brno (Czech Republic), medac specializes in small molecules, biologics (mAbs, proteins, peptides, oligonucleotides), and ADCs. They handle aseptic filling, terminal sterilization, lyophilization, and high-potent API processing down to OEL = 10 ng/m3. Manufacturing scales range from 1-50 L (small) to 50-1,500 L (large) with campaigns up to 11,000 L. They partner with Cerbios under the PROVEO brand for integrated ADC services. Over 40 years of regulatory expertise with approvals from multiple international health authorities.

NJ Bio, Inc.

India

NJ Bio, Inc. is a premier CRO/CDMO specializing in antibody-drug conjugates (ADCs), antibody-oligonucleotide conjugates, and related bioconjugation chemistry. The company provides integrated chemistry services from discovery through GMP manufacturing, including custom synthesis of payloads, linkers, drug-linkers, and bioconjugation. NJ Bio has facilities in Princeton, New Jersey with specialized laboratories for high-potency API handling.

Ofichem Group

Netherlands

Ofichem Group is a family-owned European CDMO and pharmaceutical supplier founded in 1975, headquartered in Ter Apel, Netherlands. The company provides end-to-end services from drug substance (API) development through finished drug product manufacturing, including sourcing and distribution. Ofichem has recently expanded through acquisitions of Meribel Pharma Solutions' Uppsala site (early-phase development, ADCs, oligonucleotides, PROTACs) and Avivia (formulation development).

ProteoGenix SAS

France

ProteoGenix SAS is a French antibody production company founded in 2003, providing integrated solutions for custom antibody development, recombinant protein expression, and bioproduction services. The company offers therapeutic antibody discovery, humanization using proprietary AI, ADC development, bispecific antibody development, CAR-T platforms, and custom cell line development across 6 manufacturing sites. ProteoGenix serves the therapeutics, diagnostics, research, and animal health markets.

Protheragen-ING

China

Protheragen-ING is a China-based comprehensive integrated service provider specializing in drug development and biotechnology solutions. The company offers both small molecule and large molecule (antibody, ADC, protein therapy) development and manufacturing services, with an extensive pipeline of available drug development projects spanning antibody therapies, oncolytic virotherapy, cell therapy (CAR-T), and small molecules. Protheragen is FDA-registered for API manufacture and operates project incubation and equity investment services for drug candidates.

Recipharm AB

Sweden

Rechon Life Science AB is a subsidiary/entity within the Recipharm group, the global CDMO headquartered in Stockholm, Sweden. This entry represents the same Recipharm organization (same website: recipharm.com) with its extensive global manufacturing footprint of 15+ FDA-registered FEI numbers and 52 FDA inspections. The Perplexity research confirms Recipharm's specialization in oral solid dose, inhalation, sterile manufacturing, and HPAPI capabilities. Rechon may represent a specific Recipharm site or legacy entity. Duplicate of Recipharm AB entry -- capabilities are identical.

Sterling Pharma Solutions

Ireland

Sterling Pharma Solutions is a global CDMO with over 50 years of experience providing API development and manufacturing services to pharmaceutical and biotech companies. The company specializes in high potency APIs, hazardous chemistry, controlled substances, peptides, flow chemistry, biocatalysis, and ADC bioconjugation across six facilities in the UK, Ireland, and US.

AMPAC Analytical is part of SK pharmteco, a major integrated CDMO providing custom small molecule API development and manufacturing, viral vector and gene therapy CDMO services, and comprehensive analytical testing. SK pharmteco operates FDA/EMA/PMDA-inspected facilities across the US, Korea, Ireland, and France with capabilities spanning from clinical trials through commercial scale manufacturing.

CordenPharma is a full-service CDMO providing integrated development and manufacturing of APIs, drug products, and lipid excipients across a global network of cGMP facilities in Europe and North America. The company offers capabilities spanning peptides, oligonucleotides, highly potent and oncology compounds, small molecules, injectables, lipid nanoparticles (LNPs), and oral solid dosage forms. CordenPharma is investing over EUR 500M in a new peptide manufacturing facility in Muttenz, Switzerland, and expanding its Colorado site for large-scale peptide production.

Dishman Carbogen Amcis Ltd

China

Dishman Carbogen Amcis Ltd is a global CDMO and pharmaceutical outsourcing partner with operations across India, Switzerland, UK, France, Netherlands, and China. With 30 years of experience, they offer custom API development and manufacturing up to 100 metric ton scale, drug product capabilities including highly potent compounds and ADCs, plus finished dosage forms including soft gel capsules and encapsulation. They have received successful USFDA, PMDA, and EDQM inspections.

Eurofins Biopharma Services (CDMO)

Australia

Eurofins Biopharma Services CDMO is a division of Eurofins Scientific offering integrated API and drug product outsourcing services across small molecules and biologics. The company provides services from early-stage development through commercial manufacturing including highly potent drug development, sterile manufacturing/fill-finish, lyophilization, and biologics development through its Alphora brand.

GTP Bioways

France

Duplicate entry of GTP Bioways (company ID 1f8658ec). GTP Bioways, acquired by Olon Group in 2024, is a French biologics CDMO specializing in process development and GMP manufacturing of monoclonal antibodies, recombinant proteins, bispecifics, ADCs, and nanodrugs across four sites in France.

HAS Healthcare Advanced Synthesis SA

Switzerland

HAS Healthcare Advanced Synthesis SA, based in Biasca, Switzerland, is a full-service CDMO with over 40 years of experience in pharmaceutical development and manufacturing. The company recently acquired Cerbios-Pharma SA to create a leading international CDMO group, backed by 65 Equity Partners.

Leanbio

Spain

Leanbio is a Spanish biopharmaceutical CDMO founded in 2014 by Dr. Andreu Soldevila and Albert Font, specializing in end-to-end development and manufacturing of biological products including recombinant proteins, antibodies, bioconjugates, and mRNA. Offers both microbial and mammalian production platforms. Acquired by Reig Jofre to strengthen their CDMO capabilities. Currently building a new GMP biologics facility in Sant Quirze del Valles, Barcelona, with an additional 20M EUR investment, featuring over 4,000 sqm and three manufacturing areas: one each for microbial, mammalian, and mRNA production.